TABLE 3.
Multivariate Cox proportional hazard model for LRRFS
| Characteristic | All patients | BCT | Mastectomy | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Mastectomy vs. BCT | 1.07 | 0.86 to 1.34 | 0.55 | ||||||
| Age: >50 vs. ≤ 50 years | 0.73 | 0.58 to 0.92 | 0.007 | 0.66 | 0.46 to 0.92 | 0.016 | 0.79 | 0.58 to 1.07 | 0.13 |
| Tumor size: T2–4 vs. T1 | 1.37 | 1.09 to 1.72 | 0.006 | 1.35 | 0.98 to 1.86 | 0.07 | 1.39 | 1 to 1.92 | 0.048 |
| Lymph nodes: N1–3 vs. N0 | 1.21 | 0.96 to 1.53 | 0.11 | 1.48 | 1.05 to 2.07 | 0.025 | 1.02 | 0.73 to 1.42 | 0.91 |
| Grade: III vs. I/II | 1.92 | 1.28 to 2.89 | 0.002 | 1.89 | 0.99 to 3.63 | 0.05 | 1.94 | 1.15 to 3.27 | 0.013 |
| LVI: positive vs. negative/unknown | 1.93 | 1.54 to 2.42 | <0.0001 | 2.00 | 1.43 to 2.79 | <0.0001 | 1.99 | 1.46 to 2.71 | <0.0001 |
| Resection margin: close/positive vs. free | 1.89 | 1.37 to 2.6 | <0.0001 | 2.02 | 1.32 to 3.1 | 0.001 | 1.86 | 1.14 to 3.03 | 0.013 |
| Adjuvant chemotherapy: anthracycline or taxane vs. anthracycline + taxane | 1.02 | 0.80 to 1.30 | 0.88 | 1.31 | 0.91 to 1.87 | 0.14 | 0.85 | 0.61 to 1.18 | 0.32 |
| Adjuvant chemotherapy:other vs. anthracycline + taxane | 2.01 | 1.46 to 2.77 | <0.0001 | 1.72 | 1.03 to 2.89 | 0.038 | 2.24 | 1.47 to 3.4 | 0.0002 |